Germline TP53 mutations in individuals affected by Li–Fraumeni syndrome have been linked with a predisposition to cancer, including leukemia [47], while somatic TP53 mutations in AML are generally associated with acute disease, inferior response to therapy and poor prognosis [48]. The gene discussed is TP53; the disease is leukemia.